References: Stroke and bleeding risk assessment for atrial fibrillation

  • Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med 2022;387(11):978-88. https://www.ncbi.nlm.nih.gov/pubmed/36036525
  • Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42(5):373-498. https://www.ncbi.nlm.nih.gov/pubmed/32860505
  • National Institute for Health and Care Excellence (NICE). Atrial fibrillation: diagnosis and management [ng196]. London: NICE; 2021. https://www.nice.org.uk/guidance/ng196
  • NHFA CSANZ Atrial fibrillation guideline working group, Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018;27(10):1209-66. https://www.ncbi.nlm.nih.gov/pubmed/30077228
  • Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021;23(10):1612-76. https://www.ncbi.nlm.nih.gov/pubmed/33895845